6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Company News

FDA to discuss pulmonary product from GSK, Theravance

FDA's Pulmonary-Allergy Drugs Advisory Committee will meet on March 7, 2013, to discuss an NDA from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and partner

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >